On June 11, 2025, the Delaware Court of Chancery found Alexion Pharmaceuticals liable for more than $180 million in damages to former stockholders of Syntimmune, Inc., following the Court’s September 2024 ruling that Alexion...more
6/19/2025
/ Biotechnology ,
Breach of Contract ,
Clinical Trials ,
Commercially Reasonable Efforts ,
Contract Disputes ,
Contract Terms ,
Damages ,
Life Sciences ,
Merger Agreements ,
Mergers ,
Pharmaceutical Industry
On October 1, 2019, the Delaware Court of Chancery applied the Delaware Supreme Court’s recent decision on Caremark board oversight claims in the context of operating in a highly regulated industry to allow derivative claims...more